Blue Horizon, a pure play impact investor in the future of food, has made a seed investment in Core Biogenesis which uses plants as biofactories to scale the production of high-value bioproducts like growth factors.
Blue Horizon invested in Core Biogenesis, a French startup focusing on the production of growth factors for applications in both cell therapy and cultivated meat. Core Biogenesis’ plant-based production platform has delivered several functional growth factors to date and provides unique cost-efficiency at large scale.
The current funding round will enable Core Biogenesis to expand the team that scales up production in a new facility in Strasbourg, France, while further developing their proprietary platform.
